Chronic nicotine modifies the effects of morphine on extracellular striatal dopamine and ventral tegmental GABA

Journal of Neurochemistry

Volumn 107, Issue 3, 2008, Pages 844-854

  Vihavainen, Tanja ^a   Relander, Toni R A ^a   Leiviskä, Riikka ^a   Airavaara, Mikko ^a   Tuominen, Raimo K ^a   Ahtee, Liisa ^a   Piepponen, Timo Petteri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

methyltyrosine; 3,4 dyhydroxylphenylalanine; 3 hydroxybenzylhydrazine dihydrochloride; Caudate putamen; Chronic oral nicotine treatment; Dopamine; GABA; Microdialysis; Morphine; Nipecotic acid; Nucleus accumbens; Substantia nigra; Ventral tegmental area

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; BACLOFEN; DOPA; DOPAMINE; MORPHINE; NICOTINE; NIPECOTIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; PUTAMEN; VENTRAL TEGMENTUM;

ANIMALS; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICE; MICRODIALYSIS; MORPHINE; MOTOR ACTIVITY; NARCOTICS; NEUROTRANSMITTER AGENTS; NICOTINE; NICOTINIC AGONISTS; TIME;

MUS;

EID: 53749089140     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05676.x     Document Type: Article

References (68)

1. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T. P., Saarma M. Ahtee L. (2006) In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 59, 321 329.
2. Airio J. Ahtee L. (1997) Role of cerebral dopamine and noradrenaline in the morphine-induced locomotor sensitisation in mice. Pharmacol. Biochem. Behav. 58, 379 386.
3. 3H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration. BMC Pharmacol. 4, 24.
4. Amantea D., Tessari M. Bowery N. G. (2004) Reduced G-protein coupling to the GABAB receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine. Neurosci. Lett. 355, 161 164.
5. Attila L. M. Ahtee L. (1984) Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn Schmiedebergs Arch. Pharmacol. 327, 201 207.
6. Barakat L. Bordey A. (2002) GAT-1 and reversible GABA transport in Bergmann glia in slices. J. Neurophysiol. 88, 1407 1419.
7. Benwell M. E. Balfour D. J. (1992) The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmacol. 105, 849 856.
8. Bernath S. Zigmond M. J. (1989) Dopamine may influence striatal GABA release via three separate mechanisms. Brain Res. 476, 373 376.
9. Biala G. Weglinska B. (2004) Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J. Pharm. Pharmacol. 56, 1021 1028.
10. Biala G. Weglinska B. (2006) On the mechanism of cross-tolerance between morphine- and nicotine-induced antinociception: involvement of calcium channels. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 15 21.
11. Cammack J. N. Schwartz E. A. (1993) Ions required for the electrogenic transport of GABA by horizontal cells of the catfish retina. J. Physiol. 472, 81 102.
12. Cammack J. N., Rakhilin S. V. Schwartz E. A. (1994) A GABA transporter operates asymmetrically and with variable stoichiometry. Neuron 13, 949 960.
13. Campbell K., Kalen P., Lundberg C., Wictorin K., Rosengren E. Bjorklund A. (1993) Extracellular gamma-aminobutyric acid levels in the rat caudate-putamen: monitoring the neuronal and glial contribution by intracerebral microdialysis. Brain Res. 614, 241 250.
14. Carlsson A. Lindqvist M. (1973) In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J. Neural Transm. 34, 79 91.
15. Chait L. D. Griffiths R. R. (1984) Effects of methadone on human cigarette smoking and subjective ratings. J. Pharmacol. Exp. Ther. 229, 636 640.
16. Clarke P. B., Fu D. S., Jakubovic A. Fibiger H. C. (1988) Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246, 701 708.
17. Corrigall W. A. Coen K. M. (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104, 171 176.
18. Corrigall W. A., Franklin K. B., Coen K. M. Clarke P. B. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107, 285 289.
19. Dhatt R. K., Gudehithlu K. P., Wemlinger T. A., Tejwani G. A., Neff N. H. Hadjiconstantinou M. (1995) Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J. Neurochem. 64, 1878 1883.
20. Di Chiara G. Imperato A. (1988a) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274 5278.
21. Di Chiara G. Imperato A. (1988b) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067 1080.
22. Fadda P., Scherma M., Fresu A., Collu M. Fratta W. (2003) Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50, 1 6.
23. Franklin K. B. J. Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, Inc., San Diego, CA, USA.
24. Gallo V., Patrizio M. Levi G. (1991) GABA release triggered by the activation of neuron-like non-NMDA receptors in cultured type 2 astrocytes is carrier-mediated. Glia 4, 245 255.
25. Haghparast A., Khani A., Naderi N., Alizadeh A. M. Motamedi F. (2008) Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice. Pharmacol. Biochem. Behav. 88, 385 392.
26. Houdi A. A., Dasgupta R. Kindy M. S. (1998) Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res. 799, 257 263.
27. Isola R., Zhang H., Duchemin A. M., Tejwani G. A., Neff N. H. Hadjiconstantinou M. (2002) Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse. Neurosci. Lett. 325, 67 71.
28. Johnson S. W. North R. A. (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12, 483 488.
29. Kayadjanian N., Retaux S., Menetrey A. Besson M. J. (1994) Stimulation by nicotine of the spontaneous release of [3H]gamma-aminobutyric acid in the substantia nigra and in the globus pallidus of the rat. Brain Res. 649, 129 135.
30. Kemmling A. K., Rubio M. C. Balerio G. N. (2002) Baclofen prevents morphine withdrawal irrespective of seasonal variation. Behav. Pharmacol. 13, 87 92.
31. Klitenick M. A., DeWitte P. Kalivas P. W. (1992) Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J. Neurosci. 12, 2623 2632.
32. Kuschinsky K. Hornykiewicz O. (1974) Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur. J. Pharmacol. 26, 41 50.
33. Leite-Morris K. A., Fukudome E. Y., Shoeb M. H. Kaplan G. B. (2004) GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J. Pharmacol. Exp. Ther. 308, 667 678.
34. Levi G. Gallo V. (1995) Release of neuroactive amino acid from glia, in Neuroglia (Kettenmann H. Ransom B. R., eds pp. 815 826. Oxford, New York.
35. Liu Z. H. Jin W. Q. (2004) Decrease of ventral tegmental area dopamine neuronal activity in nicotine withdrawal rats. Neuroreport 15, 1479 1481.
36. Lu Y., Grady S., Marks M. J., Picciotto M., Changeux J. P. Collins A. C. (1998) Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 287, 648 657.
37. Mansvelder H. D., Keath J. R. McGehee D. S. (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33, 905 919.
38. Paterson N. E., Bruijnzeel A. W., Kenny P. J., Wright C. D., Froestl W. Markou A. (2005) Prolonged nicotine exposure does not alter GABA(B) receptor-mediated regulation of brain reward function. Neuropharmacology 49, 953 962.
39. Pekonen K., Karlsson C., Laakso I. Ahtee L. (1993) Plasma nicotine and cotinine concentrations after chronic oral nicotine administration and challenge doses. Eur. J. Pharm. Sci. 1, 13 18.
40. Piepponen T. P., Honkanen A., Kivastik T., Zharkovsky A., Turtia A., Mikkola J. A. Ahtee L. (1999) Involvement of opioid μ1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission. Pharmacol. Biochem. Behav. 63, 245 252.
41. Pietilä K., Salminen O., Leikola-Pelho T. Ahtee L. (1996) Tolerance to nicotine's effects on striatal dopamine metabolism in nicotine-withdrawn mice. Eur. J. Pharmacol. 318, 17 22.
42. Pin J. P. Bockaert J. (1989) Two distinct mechanisms, differentially affected by excitatory amino acids, trigger GABA release from fetal mouse striatal neurons in primary culture. J. Neurosci. 9, 648 656.
43. Pokk P., Vassiljev V. Vali M. (2000) The effect of baclofen on the locomotor activity of control and small-platform-stressed mice. Pharmacol. Res. 42, 235 237.
44. Rahman S., Zhang J., Engleman E. A. Corrigall W. A. (2004) Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study. Neuroscience 129, 415 424.
45. Rea K., Cremers T. I. Westerink B. H. (2005) HPLC conditions are critical for the detection of GABA by microdialysis. J. Neurochem. 94, 672 679.
46. Risso S., DeFelice L. J. Blakely R. D. (1996) Sodium-dependent GABA-induced currents in GAT1-transfected HeLa cells. J. Physiol. 490, 691 702.
47. Saito H. (1990) Inhibitory and stimulatory effects of morphine on locomotor activity in mice: biochemical and behavioral studies. Pharmacol. Biochem. Behav. 35, 231 235.
48. Schmitz J. M., Grabowski J. Rhoades H. (1994) The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 34, 237 242.
49. Shippenberg T. S., Bals-Kubik R. Herz A. (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 265, 53 59.
50. Shippenberg T. S., Heidbreder C. Lefevour A. (1996) Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol. 299, 33 39.
51. Singer G., Wallace M. Hall R. (1982) Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat. Pharmacol. Biochem. Behav. 17, 579 581.
52. Sotomayor R., Forray M. I. Gysling K. (2005) Acute morphine administration increases extracellular DA levels in the rat lateral septum by decreasing the GABAergic inhibitory tone in the ventral tegmental area. J. Neurosci. Res. 81, 132 139.
53. Spanagel R., Herz A. Shippenberg T. S. (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55, 1734 1740.
54. Spiga R., Schmitz J. Day II. J. (1998) Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 50, 157 165.
55. Spyraki C., Fibiger H. C. Phillips A. G. (1983) Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology (Berl) 79, 278 283.
56. Story J. Stark M. J. (1991) Treating cigarette smoking in methadone maintenance clients. J. Psychoactive Drugs 23, 203 215.
57. Suh H. W., Song D. K., Choi S. R., Chung K. M. Kim Y. H. (1996) Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse. Neuropeptides 30, 479 484.
58. Tammimäki A., Pietilä K., Raattamaa H. Ahtee L. (2006) Effect of quinpirole on striatal dopamine release and locomotor activity in nicotine-treated mice. Eur. J. Pharmacol. 531, 118 125.
59. Timmerman W. Westerink B. H. (1997) Brain microdialysis of GABA and glutamate: what does it signify? Synapse 27, 242 261.
60. Vihavainen T., Mijatovic J., Piepponen T. P., Tuominen R. K. Ahtee L. (2006) Effect of morphine on locomotor activity and striatal monoamine metabolism in nicotine-withdrawn mice. Behav. Brain Res. 173, 85 93.
61. Vihavainen T., Piltonen M., Tuominen R. K., Korpi E. R. Ahtee L. (2008) Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure. Eur. J. Pharmacol. 587, 169 174.
62. Walters C. L., Cleck J. N., Kuo Y. C. Blendy J. A. (2005) μ-Opioid receptor and CREB activation are required for nicotine reward. Neuron 46, 933 943.
63. Woo S. H., Kim H. S., Yun J. S., Lee M. K., Oh K. W., Seong Y. H., Oh S. K. Jang C. G. (2001) Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity. Pharmacol. Res. 43, 335 340.
64. Yee J. M., Agulian S. Kocsis J. D. (1998) Vigabatrin enhances promoted release of GABA in neonatal rat optic nerve. Epilepsy Res. 29, 195 200.
65. Zarrindast M. R., Khoshayand M. R. Shafaghi B. (1999) The development of cross-tolerance between morphine and nicotine in mice. Eur. Neuropsychopharmacol. 9, 227 233.
66. Zarrindast M. R., Barghi-Lashkari S. Shafizadeh M. (2001) The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice. Pharmacol. Biochem. Behav. 68, 283 289.
67. Zarrindast M. R., Faraji N., Rostami P., Sahraei H. Ghoshouni H. (2003) Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol. Biochem. Behav. 74, 363 369.
68. van der Zeyden M., Oldenziel W. H., Rea K., Cremers T. I. Westerink B. H. (2008) Microdialysis of GABA and glutamate: analysis, interpretation and comparison with microsensors. Pharmacol. Biochem. Behav. 90, 135 147.